We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gene-Triggered Transporter Approach Causes Breast Cancer Cells to Self-Destruct

By LabMedica International staff writers
Posted on 09 Mar 2011
Irish Scientists have demonstrated that they can deliver a gene directly into breast cancer cells causing them to self-destruct, using a novel, minute gene transport system.

The study's findings were published February 28, 2011, in the International Journal of Pharmaceutics. Employing a transport system called a designer biomimetic vector (DBV), Dr. More...
Helen McCarthy, from Queen's University Belfast (Ireland) School of Pharmacy, funded by the Breast Cancer Campaign (London, UK), packed a gene into a nanoparticle 400 times smaller than the width of a human hair, allowing it to be delivered right into breast cancer cells in the laboratory.

The gene called iNOS (induction of nitric oxide synthase), is targeted specifically to breast cancer cells using the DBV where it forces the cells to generate lethal nitric oxide; either killing the cells outright or making them more susceptible to being destroyed by chemotherapy and radiotherapy. As this technique leaves normal healthy breast cells unaffected, this would overcome many of the toxic side effects of current treatments.

Additional study is needed but it could be trialed in patients in as little as five years. Dr. McCarthy's next step is to convert the nanoparticles into a dried powder that could be easily transported and reconstituted before being administered to patients.

Dr. McCarthy commented, "A major stumbling block to using gene therapy in the past has been the lack of an effective delivery system. Combining the designer biomimetic vector with the iNOS gene has proved successful in killing breast cancer cells in the laboratory. In the long term, I see this being used to treat people with metastatic breast cancer that has spread to the bones, ideally administered before radiotherapy and chemotherapy.”

Dr. Lisa Wilde, research information senior manager, Breast Cancer Campaign said, "Gene therapy could potentially be an exciting avenue for treating breast cancer. Although at an early stage, Dr. McCarthy's laboratory research shows that this system for delivering toxic genes to tumor cells holds great promise and we look forward to seeing how it is.”

Related Links:
Queen's University Belfast
Breast Cancer Campaign



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Automated Urinalysis Solution
UN-9000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.